Increased EZH2 expression during the adenoma‑carcinoma sequence in colorectal cancer

Ohuchi,Mayuko; Sakamoto,Yasuo; Tokunaga,Ryuma; Kiyozumi,Yuki; Nakamura,Kenichi; Izumi,Daisuke; Kosumi,Keisuke; Harada,Kazuto; Kurashige,Junji; Iwatsuki,Masaaki; Baba,Yoshifumi; Miyamoto,Yuji; Yoshida,Naoya; Shono,Takashi; Naoe,Hideaki; Sasaki,Yutaka; Baba,Hideo

doi:10.3892/ol.2018.9240

Increased EZH2 expression during the adenoma‑carcinoma sequence in colorectal cancer

Authors:
- Mayuko Ohuchi
- Yasuo Sakamoto
- Ryuma Tokunaga
- Yuki Kiyozumi
- Kenichi Nakamura
- Daisuke Izumi
- Keisuke Kosumi
- Kazuto Harada
- Junji Kurashige
- Masaaki Iwatsuki
- Yoshifumi Baba
- Yuji Miyamoto
- Naoya Yoshida
- Takashi Shono
- Hideaki Naoe
- Yutaka Sasaki
- Hideo Baba
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860‑8556, Japan, Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860‑8556, Japan
Published online on: July 31, 2018 https://doi.org/10.3892/ol.2018.9240
Pages: 5275-5281

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The adenoma‑carcinoma sequence, the sequential mutation and deletion of various genes by which colorectal cancer progresses, is a well‑established and accepted concept of colorectal cancer carcinogenesis. Proteins of the polycomb repressive complex 2 (PRC2) function as transcriptional repressors by trimethylating histone H3 at lysine 27; the activity of this complex is essential for cell proliferation and differentiation. The histone methyltransferase enhancer of zeste homolog 2 (EZH2), an essential component of PRC2, is associated with the transcriptional repression of tumor suppressor genes. EZH2 expression has previously been reported to increase with the progression of pancreatic intraductal papillary mucinous neoplasm. Thus, we hypothesized that EZH2 expression also increases during the adenoma‑carcinoma sequence of colorectal cancer. The present study investigated changes in EZH2 expression during the colorectal adenoma‑carcinoma sequence. A total of 47 patients with colorectal adenoma, 20 patients with carcinoma in adenoma and 43 patients with colorectal carcinoma who underwent surgical or endoscopic resection were enrolled in this study. Non‑cancerous tissue from the clinical specimens was also examined. The association between EZH2 expression, pathology and expression of tumor suppressor genes during colorectal carcinogenesis were analyzed. Each specimen was immunohistochemically stained for EZH2, proliferation marker protein Ki‑67 (Ki‑67), cyclin‑dependent kinase inhibitor (CDKN) 1A (p21), CDKN1B (p27) and CDKN2A (p16). Total RNA was extracted from formalin‑fixed paraffin‑embedded blocks and reverse transcription‑quantitative polymerase chain reaction analysis of these genes was performed. Ki‑67 and EZH2 expression scores increased significantly during the progression of normal mucosa to adenoma and carcinoma (P=0.009), and EZH2 expression score was positively associated with Ki‑67 expression score (P=0.02). Conversely, p21 mRNA and protein expression decreased significantly, whereas expression of p27 and p16 did not change significantly. During the carcinogenesis sequence from normal mucosa to adenoma and carcinoma, EZH2 expression increased and p21 expression decreased significantly. EZH2 may therefore contribute to the development of colorectal cancer from adenoma via suppression of p21.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
2	Khandekar MJ, Cohen P and Bruce M: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 11:886–895. 2011. View Article : Google Scholar : PubMed/NCBI
3	Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
4	Saif MW and Chu E: Biology of colorectal cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar : PubMed/NCBI
5	Issa JP: Colon cancer: It's CIN or CIMP. Clin Cancer Res. 14:5939–5940. 2008. View Article : Google Scholar : PubMed/NCBI
6	Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
7	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
8	Alkema MJ, Bronk M, Verhoeven E, Otte A, van't Veer LJ, Berns A and van Lohuizen M: Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Gene Dev. 11:226–240. 1997. View Article : Google Scholar : PubMed/NCBI
9	Kuzmichev A, Nishioka K, Erdjument-Bronmage, Tempst P and Reinberg D: Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Gene Dev. 16:2893–2905. 2002. View Article : Google Scholar : PubMed/NCBI
10	Ketel CS, Andersen EF, Vargas ML, Suh J, Strome S and Simon JA: Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes. Mol Cell Biol. 25:6857–6868. 2005. View Article : Google Scholar : PubMed/NCBI
11	Schwartz YB, Kahn TG, Nix DA, Li XY, Bourgon R, Biggin M and Pirrotta V: Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet. 38:700–705. 2006. View Article : Google Scholar : PubMed/NCBI
12	Schuettengruber B, Ganapathi M, Leblanc B, Portoso M, Jaschek R, Tolhuis B, van Lohuizen M, Tanay A and Cavalli G: Functional anatomy of polycomb and trithorax chromatin landscapes in Drosophila embryos. PLoS Biol. 7:e132009. View Article : Google Scholar : PubMed/NCBI
13	Boyer LA, Piath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, et al: Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 441:349–353. 2006. View Article : Google Scholar : PubMed/NCBI
14	Cao R and Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev. 14:155–164. 2004. View Article : Google Scholar : PubMed/NCBI
15	Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
17	Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
18	Varambally S, Dhanasekaran SM, Ahou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
19	Saramäki OR, Tammela TL, Martilkainen PM, Vessella RL and Visakorpi T: The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Gene Chromosome Canc. 45:639–645. 2006. View Article : Google Scholar
20	Li H, Cai Q, Godwin AK and Zhang R: Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res. 8:1610–1618. 2010. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H, et al: Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 20 Suppl 3:S667–S675. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kuroki H, Hayashi H, Okabe H, Hashimoto D, Takamori H, Nakahara O, Nakagawa S, Fukushima Y, Chikamoto A, Beppu T, et al: EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation. PLoS One. 9:e1009042014. View Article : Google Scholar : PubMed/NCBI
23	Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC and Hornyak TJ: EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 9:418–29. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ougolkov AV, Billim V and Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 14:6790–6796. 2008. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Abbas T and Dutta A: p21 in cancer, intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
27	Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Eng J Med. 319:525–532. 1988. View Article : Google Scholar
28	Sasaki M, Okamoto M, Sato C, Sugio K, Soejima J, Iwama T, Ikeuchi T, Tonomura A, Miyaki M and Sasazuki T: Loss of constitutional heterozygosity in colorectal tumors from patients with familial polyposis coli and those with nonpolyposis colorectal carcinoma. Cancer Res. 49:4402–4406. 1989.PubMed/NCBI
29	Goelz SE, Vogelstein B, Jamilton SR and Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 228:187–190. 1985. View Article : Google Scholar : PubMed/NCBI
30	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bukholm IK and Mesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 436:224–228. 2000. View Article : Google Scholar : PubMed/NCBI
32	Pasz-Walczak G, Kordek R and Faflik M: P21 (WAF1) expression in colorectal cancer: Correlation sith P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract. 197:683–689. 2001. View Article : Google Scholar : PubMed/NCBI
33	Hubaux R, Thu KL, Coe BP, MacAulay C, Lam S and Lam WL: EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thorac Oncol. 8:1102–1106. 2013. View Article : Google Scholar : PubMed/NCBI
34	Batchu RB, Qazi AM, Gruzdyn OV, Semaan A, Seward SM, Chamala S, Dhulipala VB, Bouwman DL, Weaver DW and Gruber SA: EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocaricinoma. Surgery. 154:739–747. 2013. View Article : Google Scholar : PubMed/NCBI
35	Yoo KH and Hennighausen L: EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 8:59–65. 2012. View Article : Google Scholar : PubMed/NCBI
36	Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005. View Article : Google Scholar : PubMed/NCBI
37	Kodach LL, Jacobe RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, Hommes DW, Offerhaus GJ, van den Brink GR and Hardwick JC: The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis. 31:1567–1575. 2010. View Article : Google Scholar : PubMed/NCBI